Amneal shareholders elect all director nominees, approve compensation and incentive plan

Amneal Pharmaceuticals, Inc.

All 11 director nominees elected with at least 84% of votes cast in favor.
Advisory say-on-pay proposal approved with 97.4% of votes cast in favor.
Ratification of Ernst & Young as auditor approved with 99.4% of votes cast.
Amended & Restated 2018 Incentive Award Plan approved with 93.3% of votes cast.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Amneal Pharmaceuticals, Inc. shareholders approved To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers at the 2023-05-09 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-05-09

Exact text from the filing

Proposal 2 : To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers: For Against Abstain Broker Non-Votes 227,413,821 3,098,184 680,576 25,513,061

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Amneal Pharmaceuticals, Inc. shareholders approved To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-09 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-05-09

Exact text from the filing

Proposal 3 : To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: For Against Abstain Broker Non-Votes 254,931,713 1,641,294 132,635 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Amneal Pharmaceuticals, Inc. shareholders approved To elect the following director nominees to hold office until the 2024 Annual Meeting of Stockholders and until their respective successors are elected and qualified at the 2023-05-09 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-05-09

Exact text from the filing

Proposal 1 : To elect the following director nominees to hold office until the 2024 Annual Meeting of Stockholders and until their respective successors are elected and qualified: For Against Abstain Broker Non-Votes Emily Peterson Alva 229,279,380 1,816,706 96,495 25,513,061 Deb Autor 229,602,211 1,483,770 106,600 25,513,061 J. Kevin Buchi 197,910,568 33,179,505 102,508 25,513,061 Jeff George 198,211,840 32,879,658 101,083 25,513,061 John Kiely 196,066,358 35,022,385 103,838 25,513,061 Paul Meister 212,151,263 18,932,673 108,645 25,513,061 Ted Nark 228,742,967 2,217,364 232,250 25,513,061 Chintu Patel 229,230,849 1,865,246 96,486 25,513,061 Chirag Patel 229,182,342 1,913,165 97,074 25,513,061 Gautam Patel 227,239,534 3,785,347 167,700 25,513,061 Shlomo Yanai 229,147,164 1,938,034 107,383 25,513,061

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Amneal Pharmaceuticals, Inc. shareholders approved To approve the Amended & Restated 2018 Incentive Award Plan at the 2023-05-09 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2023-05-09

Exact text from the filing

Proposal 4 : To approve the Amended & Restated 2018 Incentive Award Plan: For Against Abstain Broker Non-Votes 215,730,063 15,006,306 456,212 25,513,061

View on SEC.gov

63 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Amneal Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001723128-23-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.